Apollomics presents Vebreltinib data in patients with NSCLC

Apollomics announced a poster presentation at the 2024 European Society for Medical Oncology, ESMO, Congress, taking place September 13-17, 2024 in Barcelona, Spain. The poster presentation titled “Vebreltinib Efficacy and Safety in NSCLC Patients with METex14 Skipping Mutations” highlighted data from the ongoing global Phase 2 SPARTA-II trial and the Company’s partner, Avistone, Phase 2/3 KUNPENG trial in China. The analysis of the data included 108 patients without prior exposure to MET inhibitors that received vebreltinib, 200 mg BID in 28-day cycle, with 12 months of follow up data. With centrally confirmed METex14 skipping, overall response rate, ORR, to vebreltinib in treatment-naive patients was 66.7% with median duration of response, DOR, of 17.3 months and median progression free survival, PFS, of 13.8 months. Treatment-related adverse events of grade 3 or higher were reported in 48.1% of patients, with the most common being edema. No death was reported due to TEAEs.